Henry Schein (NASDAQ:HSIC) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Henry Schein (NASDAQ:HSIC) from a buy rating to a hold rating in a report issued on Saturday morning.

HSIC has been the topic of several other research reports. Evercore ISI raised shares of Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price target on the stock in a report on Tuesday, August 26th. Robert W. Baird reissued a “neutral” rating and set a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. JPMorgan Chase & Co. reduced their price objective on shares of Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Baird R W downgraded shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Wednesday. Five analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Henry Schein presently has an average rating of “Hold” and a consensus price target of $76.67.

Henry Schein Stock Down 2.2%

Shares of NASDAQ HSIC opened at $63.17 on Friday. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.49. The company has a market capitalization of $7.66 billion, a PE ratio of 20.38, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The firm’s 50-day moving average is $67.48 and its two-hundred day moving average is $68.80.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same period last year, the company earned $1.23 EPS. The firm’s revenue for the quarter was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Equities analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Large investors have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC purchased a new position in Henry Schein during the second quarter worth approximately $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein during the second quarter worth approximately $27,000. Rakuten Securities Inc. purchased a new position in Henry Schein during the first quarter worth approximately $34,000. ANTIPODES PARTNERS Ltd purchased a new position in Henry Schein during the second quarter worth approximately $43,000. Finally, Steph & Co. purchased a new position in Henry Schein during the second quarter worth approximately $44,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.